US Stock MarketDetailed Quotes
BTAI BioXcel Therapeutics
- 2.630
- +0.020+0.77%
Close Apr 26 16:00 ET
- 2.640
- +0.010+0.38%
Post 19:34 ET
80.42MMarket Cap-427P/E (TTM)
2.650High2.520Low260.30KVolume2.610Open2.610Pre Close668.38KTurnover1.20%Turnover RatioLossP/E (Static)30.58MShares29.56052wk High-1.42P/B57.05MFloat Cap1.91052wk Low--Dividend TTM21.69MShs Float71.500Historical High--Div YieldTTM4.98%Amplitude1.910Historical Low2.567Avg Price1Lot Size
BioXcel Therapeutics Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | (Q2)Jun 30, 2022 | (Q1)Mar 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -14.53%-155.01M | 30.48%-26.86M | -20.52%-37.58M | -15.42%-38.21M | -61.52%-52.35M | -64.74%-135.34M | -93.85%-38.64M | -54.39%-31.19M | -47.90%-33.1M | -65.04%-32.41M |
| Net income from continuing operations | -8.02%-179.05M | 59.39%-22.26M | -20.76%-50.49M | -42.06%-53.52M | -67.76%-52.8M | -55.01%-165.76M | -109.79%-54.81M | -55.93%-41.81M | -36.39%-37.67M | -19.32%-31.47M |
| Operating gains losses | -206.08%-436K | -125.74%-122K | --1K | ---546K | --231K | 793.48%411K | --474K | ---- | ---- | ---- |
| Depreciation and amortization | -2.75%318K | -3.70%78K | -7.06%79K | -3.57%81K | 3.90%80K | 10.10%327K | 6.58%81K | 10.39%85K | 6.33%84K | 18.46%77K |
| Other non cash items | 82.30%3.53M | 25.58%1.25M | 27.26%789K | --761K | --731K | --1.94M | --997K | --620K | ---- | ---- |
| Change In working capital | -80.60%2.02M | -193.49%-9.41M | 45.91%8.02M | 2,877.81%8.89M | -13.07%-5.48M | 108.90%10.4M | 159.47%10.07M | 242.64%5.5M | 80.14%-320K | -537.88%-4.84M |
| -Change in receivables | 171.37%177K | 367.74%664K | ---304K | ---148K | ---35K | ---248K | ---248K | --0 | --0 | --0 |
| -Change in inventory | 99.70%-6K | 104.68%27K | -615.38%-93K | 103.79%27K | 104.84%33K | ---1.99M | ---577K | ---13K | ---713K | ---682K |
| -Change in prepaid assets | 173.96%2.89M | 13.12%1.16M | 5.29%2.25M | 141.17%1.48M | 42.36%-2.01M | -3,891.26%-3.91M | -44.14%1.03M | 416.74%2.14M | -103.28%-3.59M | -595.02%-3.48M |
| -Change in payables and accrued expense | -104.29%-722K | -208.18%-10.97M | 82.88%6.17M | 88.87%7.54M | -411.98%-3.46M | 247.09%16.83M | 396.48%10.14M | 50.18%3.38M | 2,458.33%3.99M | -267.74%-676K |
| -Change in other current assets | ---- | ---- | 4.35%72K | 7.46%72K | 6.06%70K | ---- | ---- | -65.33%69K | --67K | --66K |
| -Change in other current liabilities | -8.87%-319K | -9.33%-82K | -9.46%-81K | -8.22%-79K | -8.45%-77K | -23.63%-293K | -8.70%-75K | 55.95%-74K | ---73K | ---71K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -14.53%-155.01M | 30.48%-26.86M | -20.52%-37.58M | -15.42%-38.21M | -61.52%-52.35M | -64.74%-135.34M | -93.85%-38.64M | -54.39%-31.19M | -47.90%-33.1M | -65.04%-32.41M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 85.61%-20K | 0 | 0 | -5.26%-20K | 0 | 68.76%-139K | 0 | 0 | 81.00%-19K | 62.03%-120K |
| Net PPE purchase and sale | 85.61%-20K | --0 | --0 | -5.26%-20K | --0 | 68.76%-139K | --0 | --0 | 81.00%-19K | 62.03%-120K |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 85.61%-20K | --0 | --0 | -5.26%-20K | --0 | 68.76%-139K | --0 | --0 | 81.00%-19K | 62.03%-120K |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | -72.44%26.52M | 4,146.00%2.12M | 0 | -99.62%250K | 24.15M | -6.06%96.24M | 50K | 42,221.13%30.05M | -34.85%66.14M | 0 |
| Net issuance payments of debt | --0 | --0 | --0 | ---- | ---- | --98.6M | --0 | --30M | ---- | ---- |
| Net common stock issuance | --27.03M | --2.38M | --0 | --0 | --24.66M | --0 | --0 | --0 | --0 | --0 |
| Proceeds from stock option exercised by employees | 79.51%508K | --0 | --0 | 35.14%250K | --258K | -80.54%283K | --50K | -54.29%48K | -62.78%185K | --0 |
| Net other financing activities | 61.53%-1.02M | ---252K | --0 | --0 | ---766K | ---2.65M | --0 | --0 | ---- | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | -72.44%26.52M | 4,146.00%2.12M | --0 | -99.62%250K | --24.15M | -6.06%96.24M | --50K | 42,221.13%30.05M | -34.85%66.14M | --0 |
| Net cash flow | ||||||||||
| Beginning cash position | -16.84%193.73M | -61.28%89.96M | -45.37%127.55M | -17.42%165.52M | -16.84%193.73M | 9.31%232.97M | -8.14%232.31M | -14.50%233.45M | 3.31%200.44M | 9.31%232.97M |
| Current changes in cash | -227.46%-128.5M | 35.89%-24.74M | -3,202.64%-37.58M | -215.02%-37.98M | 13.31%-28.2M | -297.71%-39.24M | -93.49%-38.59M | 94.35%-1.14M | -58.23%33.02M | -70.29%-32.53M |
| End cash Position | -66.33%65.22M | -66.33%65.22M | -61.28%89.96M | -45.37%127.55M | -17.42%165.52M | -16.84%193.73M | -16.84%193.73M | -8.14%232.31M | -14.50%233.45M | 3.31%200.44M |
| Free cash flow | -14.43%-155.03M | 30.48%-26.86M | -20.52%-37.58M | -15.41%-38.23M | -60.92%-52.35M | -64.02%-135.48M | -93.74%-38.64M | -54.26%-31.19M | -47.33%-33.12M | -63.02%-32.53M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg